ライフサイエンスコーパス: LSIL

1 respective of HPV status (Normal = 2/20,10%; LSIL = 11/52,21%; HSIL = 25/92,27%; ICC = 2/5,40%).

2 Eighty-seven (49.2%) of the 177 LSIL lesions found at baseline had cleared at the second

3 Of the 177 LSILs found at baseline, 87 (49.2%) had cleared at the s

4 atinocytes, and keratinocytes derived from a LSIL.

5 No incident qHPV type-associated anal LSILs/HSILs were detected among men naive to that type,

6 While only few normal samples, ASC and LSIL lesions, revealed copy number increases of 3q, 63%

7 results indicate distinct risks for HPV and LSIL.

8 d a pioneering CNN to differentiate HSIL and LSIL in HPV-related dysplastic lesions, during cervical

9 Incident development of HPV infection and LSIL, analyzed by various demographic, behavioral, and c

10 in HPV 16/18-positive women with ASC-US and LSIL, respectively, and was 5% in hrHPV-positive but HPV

11 n is very low or absent in normal cervix and LSILs, is readily detectable in HSILs, and is very stron

12 esting endpoint "normal/noHR-HPV" (10%) and "LSIL/noHR-HPV" (4%).

13 taset included 88,073 frames, categorized as LSIL or HSIL based on pathological analysis.

14 The multi-center ASCUS-LSIL Triage Study has shown that HPV DNA testing can be

15 at the time of enrollment into in the ASCUS-LSIL (Atypical Squamous Cells of Undetermined Significan

16 ubjects were 821 women enrolled in the ASCUS-LSIL Triage Study who tested positive for HPV-16 at entr

17 a nested case-control design from the ASCUS-LSIL Triage Study, we selected women with incident cervi

18 pecimens from 86 women enrolled in the ASCUS-LSIL Triage Study.

19 00 person-years for HPV6,11,16,18-associated LSILs/HSILs, respectively, among those previously expose

20 st vaccine-type HPV infection and associated LSILs/HSILs have not been studied.

21 tected against incident qHPV type-associated LSILs/HSILs.

22 No associations were found between LSIL regression and HPV status at baseline, sexual behav

23 the highest fold expression increase in both LSIL and HSIL compared to the other miRNAs.

24 Corresponding figures for cytologic LSILs were PPV, 39.2% (37.4%-41.1%); NPV, 96.4% (78.9%-9

25 h HPV infection in our study did not develop LSIL within a median follow-up period of 60 months.

26 e of 60 months for those who never developed LSIL.

27 from baseline (defined as the time of first LSIL diagnosis) for the 187 women with LSIL was 61 month

28 in behavioral and biological risks exist for LSIL, suggesting that HPV alone is not sufficient for th

29 ariable model showed the following risks for LSIL: HPV infection for less than 1 year (RH, 7.40; 95%

30 er or HSILs and 0.58 (95% CI, 0.37-1.04) for LSILs, compared with control subjects and adjusted for s

31 % confidence interval [CI], 0.2-0.7) and for LSILs/HPV (OR, 0.6; 95% CI, 0.3-0.9).

32 1.8-37.2) and a 5.3-fold increased risk for LSILs/HPV (95% CI, 1.2-23.7).

33 NN) to identify and differentiate low-grade (LSIL) and high grade (HSIL) squamous intraepithelial les

34 lesions or malignancy (NILM), and low-grade (LSIL) and high-grade (HSIL) squamous intraepithelial les

35 al Squamous Terminology (LAST) in low-grade (LSIL) and high-grade squamous intraepithelial lesions (H

36 elial neoplasia grade 1 [CIN1] or histologic LSIL), treatment-related adverse effects, including poss

37 -44% to 29%) against the detection of HSILs, LSILs, and ASCUS, respectively.

38 lagen I, but this effect was not observed in LSIL-derived keratinocytes.

39 Incident LSIL and HSIL were common during follow-up among HIV-pos

40 Both prevalent and incident LSIL cases were included in the analysis, with regressio

41 Age was associated with incident LSIL (adjusted odds ratio (aOR) 2.10 per 10 year older,

42 Incident LSILs and HSILs were common during follow-up among HIV-p

43 Age was associated with incident LSILs (adjusted odds ratio [aOR], 2.10 per 10-year incre

44 low-grade squamous intra-epithelial lesion (LSIL) regression in young women, and to examine the fact

45 d low-grade squamous intraepithelial lesion (LSIL) triage study (ALTS), who were monitored semiannual

46 t low-grade squamous intraepithelial lesion (LSIL) were significantly associated with the development

47 a low-grade squamous intraepithelial lesion (LSIL; benchmark indication for colposcopy).

48 r low-grade squamous intraepithelial lesion [LSIL]) and a positive HPV test of unknown duration, colp

49 low-grade squamous intra-epithelial lesions (LSIL; n = 52), high-grade (HSIL; n = 92), invasive cervi

50 high-grade squamous intraepithelial lesions (LSIL or HSIL).

51 low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/1

52 low-grade squamous intraepithelial lesions (LSIL) who were triaged with tests for hrHPV and HPV 16/1

53 low-grade squamous intraepithelial lesions (LSIL), 21 with high-grade squamous intraepithelial lesio

54 low-grade squamous intraepithelial lesions (LSIL), high-grade SILs (HSIL), and invasive carcinomas.

55 low-grade squamous intraepithelial lesions (LSIL, n = 14), and high-grade squamous intraepithelial l

56 5) or low-grade squamous epithelial lesions (LSILs; n=275) or who were cytologically normal (control

57 low-grade squamous intraepithelial lesions (LSILs) and the anal cancer precursor, high-grade squamou

58 Low-grade squamous intraepithelial lesions (LSILs) have been described as a benign cytological conse

59 low-grade squamous intraepithelial lesions (LSILs), and high-grade SILs (HSILs).

60 low-grade squamous intraepithelial lesions (LSILs); were positive for human papillomavirus (HPV) wit

61 t HPV testing could be helpful in monitoring LSIL.

62 The normal, LSIL, and HSIL cells were selected on the basis of the r

63 tion is likely to underlie the appearance of LSIL or HSIL soon after infection.

64 7475 to $101343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not b

65 follow-up, there were 109 incident cases of LSIL during the follow-up interval, with a median follow

66 one is not sufficient for the development of LSIL.

67 t significant risk factor for development of LSIL.

68 observation by cytology in the management of LSIL in female adolescents.

69 RA should not be indicated in the setting of LSILs/noHR-HPV following aLBC-based screening.

70 as about 70% for women with either ASC-US or LSIL.

71 V 16/18-negative women with either ASC-US or LSIL.

72 ned risk for HSIL associated with persistent LSIL underscores the need to closely monitor HIV-infecte

73 d declined with increasing disease severity [LSIL] (20%), HSIL, (17%), and cancer patients (7%); X2 t

74 At the second visit 18 men (16.8%) showed LSIL, and 25 (23.4%) HSIL.

75 For participants with low-grade SIL (LSIL) at baseline, risk of progression to high-grade SIL

76 ing was diagnosed as having a low-grade SIL (LSIL) on follow-up.

77 For those with low-grade SILs (LSILs) at baseline, the risk of progression to high-grad

78 /215) normal, 87.9% (20/232) low-grade SILs (LSILs), and 90.9% (149/164) high-grade SILs; P (linear a

79 actobacillus jensenii (P < 0.01) compared to LSIL.

80 Cigarette smoking was a risk specific to LSIL, supporting the role of tobacco in neoplastic devel

81 Ten samples were negative (9.5%), 63 were LSIL (60%) and 32 were HSIL (30.5%) according to the LAS

82 volving 8587 women with ASC-US and 5284 with LSIL were found.

83 volving 8587 women with ASC-US and 5284 with LSIL were found.

84 losely monitor HIV-infected adolescents with LSIL.

85 ological risks thought to be associated with LSIL are, in fact, risks for acquisition of HPV.

86 Of 393 men with LSIL at baseline, 114 had a second HRA between 0.5-2.5 y

87 Among men with LSIL at baseline, nearly half of these lesions cleared,

88 e high precancer risk (similar to those with LSIL), possibly warranting immediate colposcopy.

89 C-US and 76% (CI, 74% to 79%) for those with LSIL.

90 omen (referent), and HIV-infected women with LSIL had 9-fold (P < .0001) greater risk.

91 first LSIL diagnosis) for the 187 women with LSIL was 61 months (IQR 34-80).

92 In HIV-infected women with LSIL, CIN-3+ risk was 7% (95% CI, 3%-11%).

93 Of 393 men with LSILs at baseline, 114 underwent follow-up HRA 0.5 to 2.

94 Among men with LSILs at baseline, nearly half of these lesions cleared,